Caribou Biosciences Inc (NASDAQ: CRBU) announced results from its ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel), an allogeneic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE